Public Company News

HanchorBio Secures US Patent for Innovative SIRPα/CD47 Fusion Protein HCB101

TAIPEI and SHANGHAI and SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/ -- HanchorBio today announced that its proprietary HCB101, a SIRPα/CD47 fusion protein candidate, has been officially granted a US patent (Patent No. 12,447,195) by the United States Patent and Trademark Office (USPTO). Titled"E...

2025-10-21 19:00 1703

CAAS Introduces Rear-Wheel Active Steering Technology to Upper Mass-Market EVs in China

WUHAN, China, Oct. 21, 2025 /PRNewswire/ -- China Automotive Systems, Inc. (Nasdaq: CAAS) ("CAAS" or the "Company"), a leading power steering components and systems supplier inChina, today announced that with the rapid growth of automotive technological innovation, CAAS' subsidiary, Jingzhou Heng...

2025-10-21 18:00 990

Baidu to Report Third Quarter 2025 Financial Results on Nov 18, 2025

BEIJING, Oct. 21, 2025 /PRNewswire/ -- Baidu, Inc. (Nasdaq: BIDU; HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)) ("Baidu" or the "Company"), a leading AI company with strong Internet foundation, today announced that it will report its financial results for the Third Quarter 2025 endedSeptember...

2025-10-21 17:00 1177

Google AI Breakthrough Highlights Silmitasertib (CX-4945) as a Novel Pathway in Cancer Immunotherapy

TAIPEI and SAN DIEGO, Oct. 20, 2025 /PRNewswire/ -- Senhwa Biosciences's investigational new drug Silmitasertib (CX-4945) was recently featured in an official post by Google DeepMind, following a major breakthrough by the tech giant's biological artificial intelligence (AI) system. DeepMind re...

2025-10-21 10:49 1018

SK Biopharmaceuticals Launches Joint Venture with Eurofarma for AI-based Epilepsy Management Platform

SK Biopharmaceuticals forms a joint venture, Mentis Care, to develop an integrated epilepsy care ecosystem through AI-driven platform commercialization. SEOUL, South Korea, Oct. 20, 2025 /PRNewswire/ -- SK Biopharmaceuticals, Co., Ltd., a biotech company focusing on research, development, and co...

2025-10-21 09:20 1202

Eason Technology Limited Received NYSE American Non-Compliance Letter

HONG KONG, Oct. 20, 2025 /PRNewswire/ -- Eason Technology Limited ("Eason Technology" or the "Company") (NYSE:DXF

2025-10-21 04:59 2063

The Generation Essentials Group Reports on Half Year Performance with a ~160% Increase in Revenue

* TGE Achieved ~160% Increase in Revenue * Hospitality arm's revenue increased by over 60% * Total Net Income Surged over 70% to US$61.0 million (non-GAAP adjusted) * Total Assets amounted to US$1.25 billion (US$25.7/share) * Net asset value amounted to US$841 million (US$17.3/share) PARIS...

2025-10-20 20:45 2120

HanchorBio Showcases Pipeline Momentum with HCB101 and HCB301 Data Across Five Major Oncology Meetings in Q4 2025

Presentations highlight HCB101's differentiated profile and introduce first preclinical data from HCB301, underscoring HanchorBio's innovation in next-generation immunotherapies TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 20, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stag...

2025-10-20 19:00 1277

HD Hyundai Vice Chairman Chung Kisun Promoted to Chairman

SEOUL, South Korea, Oct. 20, 2025 /PRNewswire/ -- HD Hyundai announced that Executive Vice ChairmanChung Kisun has been promoted to Chairman in its latest executive appointments. Chung Kisun, HD Hyundai Chairm...

2025-10-20 14:24 1072

Zeekr Group to Report Third Quarter 2025 Financial Results on November 17, 2025

HANGZHOU, China, Oct. 20, 2025 /PRNewswire/ -- ZEEKR Intelligent Technology Holding Limited ("Zeekr Group" or the "Company") (NYSE: ZK), the world's leading premium new energy vehicle group, today announced that it will report its unaudited financial results for the third quarter endedSeptember 3...

2025-10-20 13:00 1091

CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025

SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the research results of the Phase Ib registrational clinical trial of satricabtagene autoleucel ("satri-cel", CT041)...

2025-10-20 08:15 1261

ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)

SUZHOU, China, Oct. 19, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616),  an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced the first disclosure...

2025-10-20 08:10 1095

Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances

SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.  (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today anno...

2025-10-20 07:00 1181

Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025

HONG KONG, Oct. 19, 2025 /PRNewswire/ -- On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study at the 2025 European Society of Medical Oncology Congress (ESMO 2025) .  COMPASSION-15 is a Phase III clinical trial evaluating cadonilimab, Ak...

2025-10-19 23:42 1511

HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet

* Ivonescimab plus chemotherapy demonstrated a median PFS of 11.14 months, PFS HR=0.60, P < 0.0001. * The absolute difference in median PFS between the two groups was 4.24 months (ΔPFS = 4.24 months), indicating significantly prolonged progression-free survival with ivonescimab combination th...

2025-10-19 23:37 1374

Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia

SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Primary plasma cell leukemia (pPCL) is a rare and highly aggressive plasma cell malignancy, often associated with complex genetic abnormalities. There is currently no standard treatment regimens, and conventional therapies for multiple myeloma are typically...

2025-10-19 14:00 1604

PINTEC's Subsidiary ZIITECH Makes Its Debut at Tech Week Singapore 2025

BEIJING, Oct. 17, 2025 /PRNewswire/ -- Pintec Technology Holdings Limited (Nasdaq: PT) ("PINTEC" or the "Company"), a leading technology platform committed to enabling innovative financial and digital solutions for businesses worldwide, today announced that its subsidiary ZIITECH PTY LTD ("ZIITEC...

2025-10-18 04:05 3270

CLPS Incorporation Reports Financial Results for the Second Half and Full Year of Fiscal 2025

HONG KONG, Oct. 17, 2025 /PRNewswire/ -- CLPS Incorporation (the "Company" or "CLPS") (Nasdaq: CLPS), today announced its financial results for the six months and full year of fiscal 2025 ended June 30, 2025. During this fiscal year, we faced a significant challenge when our long-standing and hi...

2025-10-17 21:23 3420

SparkRWA Expands AI Applications to Empower the Global Green Economy and Drive Sustainable Innovation

HONG KONG, Oct. 17, 2025 /PRNewswire/ -- GIBO Holdings Ltd. (NASDAQ: GIBO), Asia's leading innovation-driven creative ecosystem, today announced an extended application of its proprietary AI technologies under theSparkRWA Green Creator Framework, marking a major step toward integrating artificial...

2025-10-17 20:43 1864

Re-imagining Neo-Pragmatic Lifestyle: EPWK Launches Strategic Upgrade with "EPWK Curated Goods"

XIAMEN, China, Oct. 17, 2025 /PRNewswire/ -- "We grew weary of life's monotony, so we embarked on a journey to find 'EPWK Curated Goods.' Each selected item must pass our stringent 'Three Goods' standard: Good-looking, Good-to-use, and Good-surprise. We believe that truly excellent products can i...

2025-10-17 20:36 1448
1 ... 23242526272829 ... 777

Week's Top Stories